Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 534.5 DKK -1.35% Market Closed
Market Cap: 101B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Total Liabilities Peer Comparison

Comparables:
ZEAL
ASND
B
BAVA
F
FLUO
BIOPOR

Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Total Liabilities
kr7.7B
CAGR 3-Years
51%
CAGR 5-Years
62%
CAGR 10-Years
23%
Zealand Pharma A/S
CSE:ZEAL
Total Liabilities
kr759.5m
CAGR 3-Years
12%
CAGR 5-Years
24%
CAGR 10-Years
37%
Ascendis Pharma A/S
NASDAQ:ASND
Total Liabilities
€1.1B
CAGR 3-Years
87%
CAGR 5-Years
64%
CAGR 10-Years
52%
B
Bavarian Nordic A/S
CSE:BAVA
Total Liabilities
kr3.8B
CAGR 3-Years
-3%
CAGR 5-Years
41%
CAGR 10-Years
28%
F
Fluoguide AS
STO:FLUO
Total Liabilities
kr16.9m
CAGR 3-Years
11%
CAGR 5-Years
201%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Total Liabilities
kr26.7m
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
11%

See Also

What is Genmab A/S's Total Liabilities?
Total Liabilities
7.7B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Total Liabilities amounts to 7.7B DKK.

What is Genmab A/S's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
23%

Over the last year, the Total Liabilities growth was 137%. The average annual Total Liabilities growth rates for Genmab A/S have been 51% over the past three years , 62% over the past five years , and 23% over the past ten years .

Back to Top